Hemosiderosis classification: Difference between revisions
(4 intermediate revisions by the same user not shown) | |||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Based on the duration of symptoms, [[pulmonary hemosiderosis]] may be classified as either [[acute]] or [[chronic]] phase.[[Pulmonary hemosiderosis]] may be classified into three groups based on disease characteristic: first group with circulating [[Anti-GBM antibody|anti-glomerular basement membrane]] ([[Anti-GBM antibody|anti-GBM]]) antibodies, second group, with [[immune complex disease]], and the third group without known [[Immunological|immunologic]] association or ([[IPH]]). | |||
==Classification== | ==Classification== | ||
Based on the duration of symptoms, | Based on the duration of [[symptoms]], pulmonary hemosiderosis may be classified as either [[acute]] or the [[chronic]] phase. | ||
* In acute phase, patients | * In the [[acute]] phase, patients present with sudden onset of severe [[dyspnea]] and [[hemoptysis]], which, if not treated immediately, could be fatal. | ||
*In chronic phase, some children may present with weight loss and failure to thrive or hypoxemic respiratory failure. | *In the [[chronic]] phase, some children may present with [[weight loss]], and [[failure to thrive]] or hypoxemic [[respiratory failure]]. | ||
[[IPH]] may be classified into three groups based on disease characteristic: | [[IPH]] may be classified into three groups based on disease characteristic:<ref name="pmid32644388">{{cite journal |vauthors=LaFreniere K, Gupta V |title= |journal= |volume= |issue= |pages= |date= |pmid=32644388 |doi= |url=}}</ref> | ||
:*Group 1 pulmonary hemosiderosis involves PH with circulating anti-GMB antibodies which affecting the capillary system. | :*Group 1 [[pulmonary hemosiderosis]] involves PH with circulating [[Anti-GBM antibody|anti-GMB antibodies]] which affecting the [[capillary]] system. | ||
:*Group 2 pulmonary hemosiderosis involves PH with an immune complex disease such as systemic lupus erythematosus | :*Group 2 [[pulmonary hemosiderosis]] involves PH with an [[immune complex disease]] such as [[systemic lupus erythematosus]] ([[Systemic Lupus Erythematosus (SLE)|SLE]]). | ||
:*Group 3 pulmonary hemosiderosis involves no demonstrable immune system involvement. | :*Group 3 [[pulmonary hemosiderosis]] involves no demonstrable [[immune system]] involvement. | ||
==References== | ==References== |
Latest revision as of 05:48, 28 September 2020
Hemosiderosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Hemosiderosis classification On the Web |
American Roentgen Ray Society Images of Hemosiderosis classification |
Risk calculators and risk factors for Hemosiderosis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Based on the duration of symptoms, pulmonary hemosiderosis may be classified as either acute or chronic phase.Pulmonary hemosiderosis may be classified into three groups based on disease characteristic: first group with circulating anti-glomerular basement membrane (anti-GBM) antibodies, second group, with immune complex disease, and the third group without known immunologic association or (IPH).
Classification
Based on the duration of symptoms, pulmonary hemosiderosis may be classified as either acute or the chronic phase.
- In the acute phase, patients present with sudden onset of severe dyspnea and hemoptysis, which, if not treated immediately, could be fatal.
- In the chronic phase, some children may present with weight loss, and failure to thrive or hypoxemic respiratory failure.
IPH may be classified into three groups based on disease characteristic:[1]
- Group 1 pulmonary hemosiderosis involves PH with circulating anti-GMB antibodies which affecting the capillary system.
- Group 2 pulmonary hemosiderosis involves PH with an immune complex disease such as systemic lupus erythematosus (SLE).
- Group 3 pulmonary hemosiderosis involves no demonstrable immune system involvement.